These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hypolipidemic effect of the polysaccharide from Pholiota nameko.
    Author: Li H, Zhang M, Ma G.
    Journal: Nutrition; 2010 May; 26(5):556-62. PubMed ID: 19815391.
    Abstract:
    OBJECTIVE: This study was conducted to investigate the hypolipidemic effect of the polysaccharide isolated from Pholiota nameko (PNPS-1). METHODS: Hyperlipidemic Wistar rats were treated with PNPS-1 (20, 40, and 60 mg/kg orally). RESULTS: Treatment of hyperlipidemic Wistar rats with PNPS-1 led not only to significant decreases in very low-density lipoprotein/low-density lipoprotein cholesterol (-48.98% and -21.54%, 40 and 60 mg/kg), triacylglycerol (-19.70%, -17.17%, -32.32%), phospholipids (-9.90%, -19.80%, -27.08%), and consequently the atherogenic index (23.61%, 70.42%, 82.85%) and a increase in high-density lipoprotein cholesterol (69.01% and 73.35%, 40 and 60 mg/kg) in serum, but also to significant decreases in total lipids (-10.24% and -33.16%, 40 and 60 mg/kg), total cholesterol (-24.22%, -34.26%, -55.02%), triacylglycerol (-22.53% and -38.50%, 40 and 60 mg/kg), and phospholipids (-27.41%, 60 mg/kg) in the liver. Further, PNPS-1 significantly suppressed lipid peroxidation by decreasing malondialdehyde and increasing antioxidant enzymes in serum (malondialdehyde, 9.94%, -22.22%, -32.75%; superoxide dismutase, 37.26%, 101%, 114%; catalase, 32.2%, 30.02%, 36.74%; glutathione peroxidase, 31.30%, 35.56%, 52.34%) of the 20-, 40-, and 60-mg/kg PNPS-1 groups and in the liver (malondialdehyde, -32.26%, -47.85%; catalase, 97%, 117%; glutathione peroxidase, 70.70%, 78.03%) in the 40- and 60-mg/kg PNPS-1 groups (superoxide dismutase, 24.35%, 67.49%, 234%). PNPS-1 was also effective in lowering body weight and some visceral weights (liver, heart, and kidney) in treated rats, except for the lung. PNPS-1 also ameliorated the pathologic changes in coronary arteries of hyperlipidemic rats. CONCLUSION: These results suggested that PNPS-1 significantly suppresses the development of hyperlipidemia and might be used as a potential therapeutic agent for hyperlipidemia.
    [Abstract] [Full Text] [Related] [New Search]